< Back to search
Filter
1
Featured

A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

for
Non Small Cell Lung Cancer
Location: Levis, Greenfield Park, Montreal, Brampton,
Sponsor: AbbVie

Sex: All

Age: 18+

Code: NCT04928846

Phase3, Recruiting
Featured

A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation

for
Non-Small Cell Lung Cancer
Location: New Haven CT, Mineola NY, The Bronx NY, New York NY,
Sponsor: Hoffmann-La Roche

Sex: All

Age: 18+

Code: NCT05789082

Phase1, Phase2, Recruiting
Featured

A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

for
Non-Small Cell Lung Cancer
Location: New Haven CT, Westbury NY, The Bronx NY, Teaneck NJ,
Sponsor: AbbVie

Sex: All

Age: 18+

Code: NCT06568939

Phase2, Recruiting
Featured

A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)

for
Non-small Cell Lung Cancer
Location: Boston MA, New Haven CT, Lebanon NH, New York NY,
Sponsor: Genentech, Inc.

Sex: All

Age: 18+

Code: NCT04302025

Phase2, Recruiting
Featured

A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

for
Non-Small Cell Lung Cancer
Location: Lebanon NH, East Brunswick NJ, Rockledge FL, Brampton,
Sponsor: AbbVie

Sex: All

Age: 18+

Code: NCT07155187

Phase2, Phase3, Recruiting

Interested in new non small cell lung cancer trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image
Featured

Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

for
Non-Small Cell Lung Cancer
Location: Winter Haven FL, Athens GA, Cincinnati OH, Lexington KY,
Sponsor: AbbVie

Sex: All

Age: 18+

Code: NCT06236438

Phase2, Phase3, Recruiting
Featured

A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

for
Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer
Location: Rimouski, Boston MA, Worcester MA, Hartford CT, Quebec,
Sponsor: Hoffmann-La Roche

Sex: All

Age: 18+

Code: NCT06793215

Phase3, Recruiting
Featured

Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations

for
Non Small Cell Lung Carcinoma
Location: Boston MA, Shirley NY, East Brunswick NJ, Easton PA,
Sponsor: AbbVie

Sex: All

Age: 18+

Code: NCT06772623

Phase1, Phase2, Recruiting
Active & Responsive

JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer

for
Non-Small Cell Lung Cancer
Location: Neptune City NJ, Montreal, Syracuse NY, Ottawa, Toronto,
Sponsor: University of Texas Southwestern Medical Center

Sex: All

Age: 18+

Code: NCT02468024

Phase3, Recruiting
Active & Responsive

A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations

for
Cancer, PDAC - Pancreatic Ductal Adenocarcinoma,
Location: Boston MA, New York NY, Fairfax VA, Durham NC,
Sponsor: Alterome Therapeutics, Inc.

Sex: All

Age: 18+

Code: NCT06835569

Phase1, Recruiting
Active & Responsive

ILKN421H Plus Pembrolizumab in Advanced Non-Small Cell Lung Cancer

for
Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC),
Location: Fort Worth TX, Los Angeles CA
Sponsor: iLeukon Therapeutics, Inc.

Sex: All

Age: 18+

Code: NCT07452224

Phase2, Recruiting
Active & Responsive

A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression

for
Solid Tumor, Adult, Colorectal Cancer, Non-Small Cell Lung,
Location: New York NY, Jacksonville FL, Tampa FL, Columbus OH,
Sponsor: A2 Biotherapeutics Inc.

Sex: All

Age: 18+

Code: NCT06682793

Phase1, Phase2, Recruiting
Active & Responsive

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

for
Cancer, Metastatic, Cancer, Cancer of Pancreas, Cancer of Liver,
Location: Scarborough ME, Worcester MA, Hartford CT, Norwalk CT,
Sponsor: Massive Bio, Inc.

Sex: All

Age: 0+

Code: NCT03452774

Recruiting
Active & ResponsiveNew

A Phase 1 and 2 Study of VMD-102 in Hepatocellular Carcinoma and Other Solid Tumors

for
Hepatocellular Carcinoma (HCC), Metastatic Uveal Melanoma,
Location: Scottsdale AZ
Sponsor: VM Discovery, Inc.

Sex: All

Age: 18 - 70+

Code: NCT07636785

Phase1, Phase2, Recruiting
Active & ResponsiveNew

Study of Neoadjuvant Cemiplimab and Dupilumab in Early-Stage Non-Small Cell Lung Cancer

for
Non-Small Cell Lung Cancer, Immunotherapy, Neoadjuvant Therapy
Location: Montreal
Sponsor: Centre hospitalier de l'Université de Montréal (CHUM)

Sex: All

Age: 18+

Code: NCT06743581

Recruiting
Active & Responsive

Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer

for
Lung Cancer, Small-cell Lung Cancer, Non Small Cell Lung Cancer
Location: Philadelphia PA
Sponsor: Fox Chase Cancer Center

Sex: All

Age: 18+

Code: NCT05800587

Phase2, Recruiting
Active & Responsive

Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)

for
Non Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma
Location: Fairfax VA, Huntersville NC, Nashville TN,
Sponsor: Phanes Therapeutics

Sex: All

Age: 18+

Code: NCT05431270

Phase1, Phase2, Recruiting
Active & Responsive

A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors

for
Advanced Solid Tumor, Adult, ERBB2 Altered Breast Cancer,
Location: New Haven CT, Lake Success NY, New York NY, Fairfax VA,
Sponsor: Cogent Biosciences, Inc.

Sex: All

Age: 18+

Code: NCT07361562

Phase1, Recruiting
Active & Responsive

Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing

for
Solid Tumor, Adult, Colorectal Cancer,
Location: New York NY, Jacksonville FL, Tampa FL, Columbus OH,
Sponsor: A2 Biotherapeutics Inc.

Sex: All

Age: 18+

Code: NCT04981119

Recruiting
Active & Responsive

First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations

for
Non-Small Cell Lung Cancer, NSCLC,
Location: Philadelphia PA, Fairfax VA, Charlotte NC, Nashville TN,
Sponsor: Pierre Fabre Medicament

Sex: All

Age: 18+

Code: NCT06043817

Phase1, Phase2, Recruiting